In addition, different studies that have investigated the action of CAR in in vivo inflammatory models, such as vascular inflammation [53], colitis [11], neuroinflammation (Alzheimer-like phenotype model) [54], and arthritis [4], associated the anti-inflammatory effects of this compound through a cross-activation between the CB2 receptor and the peroxisome proliferator-activated gamma receptor (PPRA-γ). Here, PPARG is linked to colitis.